198904-77-7

Basic information

• Product Name: (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester
• Synonyms: (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester
• CAS NO: 198904-77-7
• Molecular Weight: 303.359
• Mol File: 198904-77-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester(198904-77-7)
• EPA Substance Registry System: (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester(198904-77-7)

Safety Data

• Hazardous Substances Data: 198904-77-7(Hazardous Substances Data)

Upstream product

• 20859-02-3 L-tert-Leucine 
• 870-46-2 t-butoxycarbonylhydrazine 
• 162537-11-3 (S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid 

Downstream Products

• 198904-81-3 ((S)-1-{N'-[4-(2-tert-Butyl-2H-tetrazol-5-yl)-benzyl]-hydrazinocarbonyl}-2,2-dimethyl-propyl)-carbamic acid methyl ester 
• 198904-20-0 ((S)-1-{N'-[4-(2-tert-Butyl-2H-tetrazol-5-yl)-benzyl]-N'-[(2S,3S)-2-hydroxy-3-((S)-2-methoxycarbonylamino-3,3-dimethyl-butyrylamino)-4-phenyl-butyl]-hydrazinocarbonyl}-2,2-dimethyl-propyl)-carbamic acid methyl ester 
• 857904-01-9 Methyl (1S)-2,2-dimethyl-1-({(2E)-2-[4-(2-pyridinyl)benzylidene]hydrazino}carbonyl)propylcarbamate 
• 857904-02-0 {(S)-2,2-dimethyl-1-[N'-(4-pyridin-2-yl-benzyl)-hydrazinocarbonyl]-propyl}-carbamic acid methyl ester 
• 857904-03-1 {(1S,2S)-1-benzyl-2-hydroxy-3-[N'-((S)-2-methoxycarbonylamino-3,3-dimethyl-butyryl)-N-(4-pyridin-2-yl-benzyl)-hydrazino]-propyl}-carbamic acid tert-butyl ester 
• 857900-57-3 methyl (S)-1-(2-((2S,3S)-3-amino-2-hydroxy-4-phenylbutyl)-2-benzylhydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 857904-19-9 methyl (S)-1-(2-benzyl-2-((2S,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 857900-54-0 {(S)-1-[N'-((2S,3S)-3-amino-2-hydroxy-4-phenyl-butyl)-N'-(4-pyridin-2-yl-benzyl)-hydrazinocarbonyl]-2,2-dimethyl-propyl}-carbamic acid methyl ester 
• 872703-56-5 [(1S)-1-(N'-benzyl-hydrazinocarbonyl)-2,2-dimethyl-propyl]carbamic acid methyl ester 
• 1313358-26-7 methyl (1R,3S)-3-((2S,3S)-3-hydroxy-4-(2-((S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl)-1-(4-(pyridin-2-yl)benzyl)hydrazinyl)-1-phenylbutan-2-ylcarbamoyl)-2,2-dimethylcyclobutylcarbamate 
• 1313358-27-8 methyl (S)-1-(2-((2S,3S)-3-((1S,3R)-3-(tert-butoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-28-9 methyl (S)-1-(2-((2S,3S)-3-((1S,3R)-3-acetamido-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-29-0 methyl (S)-1-(2-((2S,3S)-2-hydroxy-3-((1R,3S)-3-(methoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-30-3 methyl (S)-1-(2-((2S,3S)-3-((1R,3S)-3-(tert-butoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridin-2-yl)benzyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 

Relevant articles and documents

PROTEASE INHIBITORS HAVING ENHANCED FEATURES

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.

ANTIVIRAL PROTEASE INHIBITORS

The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and /or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.